Subclinical and asymptomatic parathyroid disease

implications of emerging data

David P. Macfarlane, Ning Yu, Graham P. Leese

    Research output: Contribution to journalArticle

    15 Citations (Scopus)

    Abstract

    Primary hyperparathyroidism, a disorder in which there is a tendency for hypercalcaemia caused by autonomous overproduction of parathyroid hormone, is common, especially in postmenopausal women. Although parathyroidectomy is indicated for symptomatic patients, most individuals with the disorder are asymptomatic and without classic complications, such as renal stones and osteoporosis, at diagnosis. Consensus guidelines suggest which individuals might be suitable for medical follow-up rather than parathyroidectomy, but there are no long-term randomised controlled trials to support the safety of medical surveillance, and some patients progress with time. Data from observational studies suggest that cardiovascular morbidity and mortality are increased in patients with primary hyperparathyroidism, and might be predicted by parathyroid hormone concentrations, even in individuals with asymptomatic primary hyperparathyroidism. Whether parathyroidectomy improves cardiovascular outcomes in patients with asymptomatic primary hyperparathyroidism is unproven, but data suggest that surgery decreases fracture risk and might improve neuropsychological symptoms. Studies also show that patients with normocalcaemic (subclinical) hyperparathyroidism and hypoparathyroidism have a low risk of progression to overt disease, but their long-term risks are not defined. In this Review, we explore the increasing range of asymptomatic parathyroid disorders, focusing on current evidence about their natural history and potential complications, with a particular emphasis on primary hyperparathyroidism.
    Original languageEnglish
    Pages (from-to)329-340
    Number of pages12
    JournalThe Lancet: Diabetes and Endocrinology
    Volume1
    Issue number4
    DOIs
    Publication statusPublished - 2013

    Fingerprint

    Parathyroid Diseases
    Asymptomatic Diseases
    Primary Hyperparathyroidism
    Parathyroidectomy
    Parathyroid Hormone
    Hypoparathyroidism
    Hyperparathyroidism
    Hypercalcemia
    Natural History
    Osteoporosis
    Observational Studies
    Randomized Controlled Trials
    Guidelines
    Morbidity
    Kidney
    Safety
    Mortality

    Cite this

    @article{be7d9ce875fb4e129c13c1dbaaddab11,
    title = "Subclinical and asymptomatic parathyroid disease: implications of emerging data",
    abstract = "Primary hyperparathyroidism, a disorder in which there is a tendency for hypercalcaemia caused by autonomous overproduction of parathyroid hormone, is common, especially in postmenopausal women. Although parathyroidectomy is indicated for symptomatic patients, most individuals with the disorder are asymptomatic and without classic complications, such as renal stones and osteoporosis, at diagnosis. Consensus guidelines suggest which individuals might be suitable for medical follow-up rather than parathyroidectomy, but there are no long-term randomised controlled trials to support the safety of medical surveillance, and some patients progress with time. Data from observational studies suggest that cardiovascular morbidity and mortality are increased in patients with primary hyperparathyroidism, and might be predicted by parathyroid hormone concentrations, even in individuals with asymptomatic primary hyperparathyroidism. Whether parathyroidectomy improves cardiovascular outcomes in patients with asymptomatic primary hyperparathyroidism is unproven, but data suggest that surgery decreases fracture risk and might improve neuropsychological symptoms. Studies also show that patients with normocalcaemic (subclinical) hyperparathyroidism and hypoparathyroidism have a low risk of progression to overt disease, but their long-term risks are not defined. In this Review, we explore the increasing range of asymptomatic parathyroid disorders, focusing on current evidence about their natural history and potential complications, with a particular emphasis on primary hyperparathyroidism.",
    author = "Macfarlane, {David P.} and Ning Yu and Leese, {Graham P.}",
    year = "2013",
    doi = "10.1016/S2213-8587(13)70083-4",
    language = "English",
    volume = "1",
    pages = "329--340",
    journal = "The Lancet: Diabetes and Endocrinology",
    issn = "2213-8587",
    publisher = "Elsevier",
    number = "4",

    }

    Subclinical and asymptomatic parathyroid disease : implications of emerging data. / Macfarlane, David P. ; Yu, Ning; Leese, Graham P.

    In: The Lancet: Diabetes and Endocrinology, Vol. 1, No. 4, 2013, p. 329-340.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Subclinical and asymptomatic parathyroid disease

    T2 - implications of emerging data

    AU - Macfarlane, David P.

    AU - Yu, Ning

    AU - Leese, Graham P.

    PY - 2013

    Y1 - 2013

    N2 - Primary hyperparathyroidism, a disorder in which there is a tendency for hypercalcaemia caused by autonomous overproduction of parathyroid hormone, is common, especially in postmenopausal women. Although parathyroidectomy is indicated for symptomatic patients, most individuals with the disorder are asymptomatic and without classic complications, such as renal stones and osteoporosis, at diagnosis. Consensus guidelines suggest which individuals might be suitable for medical follow-up rather than parathyroidectomy, but there are no long-term randomised controlled trials to support the safety of medical surveillance, and some patients progress with time. Data from observational studies suggest that cardiovascular morbidity and mortality are increased in patients with primary hyperparathyroidism, and might be predicted by parathyroid hormone concentrations, even in individuals with asymptomatic primary hyperparathyroidism. Whether parathyroidectomy improves cardiovascular outcomes in patients with asymptomatic primary hyperparathyroidism is unproven, but data suggest that surgery decreases fracture risk and might improve neuropsychological symptoms. Studies also show that patients with normocalcaemic (subclinical) hyperparathyroidism and hypoparathyroidism have a low risk of progression to overt disease, but their long-term risks are not defined. In this Review, we explore the increasing range of asymptomatic parathyroid disorders, focusing on current evidence about their natural history and potential complications, with a particular emphasis on primary hyperparathyroidism.

    AB - Primary hyperparathyroidism, a disorder in which there is a tendency for hypercalcaemia caused by autonomous overproduction of parathyroid hormone, is common, especially in postmenopausal women. Although parathyroidectomy is indicated for symptomatic patients, most individuals with the disorder are asymptomatic and without classic complications, such as renal stones and osteoporosis, at diagnosis. Consensus guidelines suggest which individuals might be suitable for medical follow-up rather than parathyroidectomy, but there are no long-term randomised controlled trials to support the safety of medical surveillance, and some patients progress with time. Data from observational studies suggest that cardiovascular morbidity and mortality are increased in patients with primary hyperparathyroidism, and might be predicted by parathyroid hormone concentrations, even in individuals with asymptomatic primary hyperparathyroidism. Whether parathyroidectomy improves cardiovascular outcomes in patients with asymptomatic primary hyperparathyroidism is unproven, but data suggest that surgery decreases fracture risk and might improve neuropsychological symptoms. Studies also show that patients with normocalcaemic (subclinical) hyperparathyroidism and hypoparathyroidism have a low risk of progression to overt disease, but their long-term risks are not defined. In this Review, we explore the increasing range of asymptomatic parathyroid disorders, focusing on current evidence about their natural history and potential complications, with a particular emphasis on primary hyperparathyroidism.

    UR - http://www.scopus.com/inward/record.url?scp=84886050771&partnerID=8YFLogxK

    U2 - 10.1016/S2213-8587(13)70083-4

    DO - 10.1016/S2213-8587(13)70083-4

    M3 - Article

    VL - 1

    SP - 329

    EP - 340

    JO - The Lancet: Diabetes and Endocrinology

    JF - The Lancet: Diabetes and Endocrinology

    SN - 2213-8587

    IS - 4

    ER -